Our platform
Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy. We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies.
1. Patient cells
2. Add gene editing complex
3. Done
Quick facts
Non-viral delivery
Natural uptake mechanism
High gene editing efficiency
High cell viability
Excellent intrinsic safety
Simple implementation
Low manufacturing costs
High scalability
R&D pipeline
We’re on a mission to make genetic treatments safer and more effective. Our primary focus is on improving how we deliver CRISPR/Cas technology to cells for ex vivo therapies, targeting breakthroughs in immuno-oncology (CAR-T and TCR therapies) and hematology. Every day, we work to drive forward the treatments of tomorrow.
Opportunities
We’ve developed a game-changing, modular delivery platform, designed for easy integration with the therapeutic development processes of our strategic partners. This platform sets a new standard in gene therapy, accelerating the path to patient care.
CAR-T
Our technology revolutionizes CAR-T cell therapy, allowing precise editing and integration of chimeric antigen receptors (CARs). This enhances the accuracy of cancer-targeting immune responses.
CRISPR/Cas9
We’ve mastered the delivery of CRISPR-Cas9 (RNP complexes) into cells, paving the way for precise genome editing. Our technology facilitates a multitude of research and therapeutic possibilities.
Base editors
Our system delivers Base editors into cells, targeting specific DNA changes without causing double-strand breaks. This approach significantly enhances the safety and reliability of gene editing.
Prime editors
Our technology excels at introducing Prime editors into cells. This enables precise and controlled DNA sequence modifications with accuracy and minimal off-target effects.
We’re supported by
